TOVX
Theriva Biologics, Inc.
AMEXHealthcareBiotechnologyUS
Rating:B-
Company Profile
CEO
Steven A. Shallcross
IPO Date
2006-12-18
Sector
Healthcare
Industry
Biotechnology
Exchange
AMEX
Country
US
Theriva Biologics, Inc.
CEO
Steven A. Shallcross
IPO Date
2006-12-18
Sector
Healthcare
Industry
Biotechnology
Exchange
AMEX
Country
US
| 75,000 |
| $0.24 |
| 6 Jan 2026 | Kraws Jeffrey J | director | A-Award | Acquired | 75,000 | $0.24 |
| 6 Jan 2026 | Wolf Jeffrey Alan | director | A-Award | Acquired | 75,000 | $0.24 |
| 1 May 2025 | MONAHAN JOHN J | director | A-Award | Acquired | 25,000 | $1.41 |
| 1 May 2025 | Kraws Jeffrey J | director | A-Award | Acquired | 25,000 | $1.41 |
| 1 May 2025 | Wolf Jeffrey Alan | director | A-Award | Acquired | 25,000 | $1.41 |
| 1 May 2025 | SHALLCROSS STEVEN A | director, officer: CEO and CFO | A-Award | Acquired | 190,000 | $1.41 |
| 15 Dec 2023 | MONAHAN JOHN J | director | A-Award | Acquired | 110,000 | $0.59 |
| 15 Dec 2023 | Kraws Jeffrey J | director | A-Award | Acquired | 110,000 | $0.59 |